Phaseline

Targets › TACC3

TACC3 (Transforming acidic coiled-coil-containing protein 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). (UniProt, Q9Y6A5)

Open in Phaseline: the race on TACC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
A2A PharmaceuticalsAO-252
TACC3 protein-protein interaction (PPI) inhibitor
TACC3Phase 1Solid Tumor MalignanciesJan 2027

Conditions

Solid Tumor Malignancies (1)

Modalities

small molecule (1)

Companies

A2A Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.